Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study

Keith A. Hawkins, Richard S E Keefe, Bruce K. Christensen, Jean Addington, Scott W. Woods, Jennifer Callahan, Robert B. Zipursky, Diana O. Perkins, Mauricio Tohen, Alan Breier, Thomas H. McGlashan

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Method: Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. Results: Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. Conclusions: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalSchizophrenia Research
Volume105
Issue number1-3
DOIs
StatePublished - Oct 2008

Fingerprint

North America
Double-Blind Method
Psychotic Disorders
olanzapine
Therapeutics
Random Allocation
Schizophrenia
Placebos
Prodromal Symptoms
Preexisting Condition Coverage
Uncertainty

Keywords

  • Course
  • Double blind
  • First episode
  • Neuropsychological
  • Olanzapine
  • Prodrome
  • Psychosis
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Hawkins, K. A., Keefe, R. S. E., Christensen, B. K., Addington, J., Woods, S. W., Callahan, J., ... McGlashan, T. H. (2008). Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research, 105(1-3), 1-9. https://doi.org/10.1016/j.schres.2008.07.008

Neuropsychological course in the prodrome and first episode of psychosis : Findings from the PRIME North America Double Blind Treatment Study. / Hawkins, Keith A.; Keefe, Richard S E; Christensen, Bruce K.; Addington, Jean; Woods, Scott W.; Callahan, Jennifer; Zipursky, Robert B.; Perkins, Diana O.; Tohen, Mauricio; Breier, Alan; McGlashan, Thomas H.

In: Schizophrenia Research, Vol. 105, No. 1-3, 10.2008, p. 1-9.

Research output: Contribution to journalArticle

Hawkins, KA, Keefe, RSE, Christensen, BK, Addington, J, Woods, SW, Callahan, J, Zipursky, RB, Perkins, DO, Tohen, M, Breier, A & McGlashan, TH 2008, 'Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study', Schizophrenia Research, vol. 105, no. 1-3, pp. 1-9. https://doi.org/10.1016/j.schres.2008.07.008
Hawkins, Keith A. ; Keefe, Richard S E ; Christensen, Bruce K. ; Addington, Jean ; Woods, Scott W. ; Callahan, Jennifer ; Zipursky, Robert B. ; Perkins, Diana O. ; Tohen, Mauricio ; Breier, Alan ; McGlashan, Thomas H. / Neuropsychological course in the prodrome and first episode of psychosis : Findings from the PRIME North America Double Blind Treatment Study. In: Schizophrenia Research. 2008 ; Vol. 105, No. 1-3. pp. 1-9.
@article{4e87ee33036047e38c9fa0b2fdd0029a,
title = "Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study",
abstract = "Objective: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Method: Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. Results: Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. Conclusions: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.",
keywords = "Course, Double blind, First episode, Neuropsychological, Olanzapine, Prodrome, Psychosis, Schizophrenia, Treatment",
author = "Hawkins, {Keith A.} and Keefe, {Richard S E} and Christensen, {Bruce K.} and Jean Addington and Woods, {Scott W.} and Jennifer Callahan and Zipursky, {Robert B.} and Perkins, {Diana O.} and Mauricio Tohen and Alan Breier and McGlashan, {Thomas H.}",
year = "2008",
month = "10",
doi = "10.1016/j.schres.2008.07.008",
language = "English (US)",
volume = "105",
pages = "1--9",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Neuropsychological course in the prodrome and first episode of psychosis

T2 - Findings from the PRIME North America Double Blind Treatment Study

AU - Hawkins, Keith A.

AU - Keefe, Richard S E

AU - Christensen, Bruce K.

AU - Addington, Jean

AU - Woods, Scott W.

AU - Callahan, Jennifer

AU - Zipursky, Robert B.

AU - Perkins, Diana O.

AU - Tohen, Mauricio

AU - Breier, Alan

AU - McGlashan, Thomas H.

PY - 2008/10

Y1 - 2008/10

N2 - Objective: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Method: Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. Results: Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. Conclusions: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.

AB - Objective: There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Method: Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments. Results: Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects. Conclusions: Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.

KW - Course

KW - Double blind

KW - First episode

KW - Neuropsychological

KW - Olanzapine

KW - Prodrome

KW - Psychosis

KW - Schizophrenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=52949095724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949095724&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.07.008

DO - 10.1016/j.schres.2008.07.008

M3 - Article

C2 - 18774696

AN - SCOPUS:52949095724

VL - 105

SP - 1

EP - 9

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -